AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
olutasidenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| isocitrate dehydrogenase inhibitors | 5693 | 1887014-12-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1). In patients with AML, susceptible IDH1 mutations are defined as those leading to increased levels of 2- hydroxyglutarate (2-HG) in the leukemia cells and where efficacy is predicted by 1) clinically meaningful remissions with the recommended dose of olutasidenib and/or 2) inhibition of mutant IDH1 enzymatic activity at concentrations of olutasidenib sustainable at the recommended dosage according to validated methods. The most common of such mutations in patients with AML are R132H and R132C substitutions. In vitro, olutasidenib inhibited mutated IDH1 R132H, R132L, R132S, R132G, and R132C proteins; wild-type IDH1 or mutated IDH2 proteins were not inhibited. Olutasidenib inhibition of mutant IDH1 led to decreased 2-HG levels in vitro and in in vivo xenograft models.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PRKDC,STK33,TEK,TTK | 28 | |||
| kinase-selectivity-class | AXL,CDK9,GRK2,MAPK7,PIK3CB,PIK3CD,TEK,UHMK1 | 8 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 1, 2022 | FDA | RIGEL PHARMS INC |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XM03 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Isocitrate dehydrogenase (IDH) inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
Related Drugs by ATC class:
L01XM Isocitrate dehydrogenase (IDH) inhibitors 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Acute myeloid leukemia, disease | indication | 91861009 | |
| Relapsing acute myeloid leukemia with a susceptible IDH1 mutation | indication | ||
| Refractory acute myeloid leukemia with a susceptible IDH1 mutation | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | 12275715 | Sept. 18, 2035 | A METHOD OF TREATING AN ADULT PATIENT WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA HAVING A SUSCEPTIBLE IDH1 MUTATION |
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | 9834539 | Sept. 18, 2035 | A METHOD OF TREATING A CANCER WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML) |
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | 11013733 | May 16, 2039 | A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML) |
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | 11013734 | May 16, 2039 | A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION |
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | 11376246 | May 16, 2039 | A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION |
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | 11497743 | May 16, 2039 | A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION |
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | 11738018 | July 17, 2039 | A METHOD OF TREATING AN ADULT PATIENT WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA HAVING A SUSCEPTIBLE IDH1 MUTATION |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | Dec. 1, 2027 | NEW CHEMICAL ENTITY |
| 150MG | REZLIDHIA | RIGEL PHARMS | N215814 | Dec. 1, 2022 | RX | CAPSULE | ORAL | Dec. 1, 2029 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH A SUSCEPTIBLE ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION AS DETECTED BY AN FDA-APPROVED TEST |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Isocitrate dehydrogenase [NADP] cytoplasmic | Enzyme | INHIBITOR | IC50 | 7.67 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Isocitrate dehydrogenase [NADP], mitochondrial | Enzyme | IC50 | 4.56 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| CHEBI:757082 | CHEBI |
| CHEMBL4297610 | ChEMBL_ID |
| C000710173 | MESH_SUPPLEMENTAL_RECORD_UI |
| 10319 | IUPHAR_LIGAND_ID |
| DB16267 | DRUGBANK_ID |
| 4041886 | VANDF |
| C5235389 | UMLSCUI |
| PWV | PDB_CHEM_ID |
| 11036 | INN_ID |
| D12483 | KEGG_DRUG |
| 118955396 | PUBCHEM_CID |
| 364106 | MMSL |
| 41136 | MMSL |
| d09955 | MMSL |
| 019241 | NDDF |
| 0T4IMT8S5Z | UNII |
| 2623641 | RXNORM |
| 0T4IMT8S5Z | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| REZLIDHIA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71332-005 | CAPSULE | 150 mg | ORAL | NDA | 28 sections |
| REZLIDHIA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71332-005 | CAPSULE | 150 mg | ORAL | NDA | 28 sections |